Literature DB >> 19039293

Nanoparticulate delivery of diphtheria toxin DNA effectively kills Mesothelin expressing pancreatic cancer cells.

Shayna L Showalter1, Yu-Hung Huang, Agneszka Witkiewicz, Christina L Costantino, Charles J Yeo, Jordan J Green, Robert Langer, Daniel G Anderson, Janet A Sawicki, Jonathan R Brody.   

Abstract

Pancreatic cancer is the fourth leading cause of cancer-related deaths in this country, and there is currently no effective targeted treatment for this deadly disease. A dire need exists to rapidly translate our molecular understanding of this devastating disease into effective, novel therapeutic options. Mesothelin is a candidate target protein shown by a number of laboratories to be specifically overexpressed in pancreatic cancers and not in the adjacent normal tissue. Translational investigations have shown promising results using this molecule as a therapeutic target (e.g., vaccine strategies). In addition, the mesothelin promoter has been cloned and dissected and can therefore be used as a vehicle for regulating expression of DNA sequences. Using a novel, proven, biodegradable nanoparticulate system, we sought to target mesothelin-expressing pancreatic cancer cells with a potent suicide gene, diphtheria toxin-A (DT-A). We first confirmed reports that a majority of pancreatic cancer cell lines and resected pancreatic ductal adenocarcinoma specimens overexpressed mesothelin at the mRNA and protein levels. High mesothelin-expressing pancreatic cancer cell lines produced more luciferase than cell lines with undetectable mesothelin expression when transfected with a luciferase sequence under the regulation of the mesothelin promoter. We achieved dramatic inhibition of protein translation (>95%) in mesothelin-expressing pancreatic cancer cell lines when DT-A DNA, driven by the mesothelin promoter, was delivered to pancreatic cancer cells. We show that this inhibition effectively targets the death of pancreatic cancer cells that overexpress mesothelin. The work presented here provides evidence that this strategy will work in pre-clinical mouse pancreatic cancer models, and suggests that such a strategy will work in the clinical setting against the majority of pancreatic tumors, most of which overexpress mesothelin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19039293      PMCID: PMC3218426          DOI: 10.4161/cbt.7.10.6562

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  43 in total

Review 1.  Diphtheria toxin: mode of action and structure.

Authors:  R J Collier
Journal:  Bacteriol Rev       Date:  1975-03

2.  Repression of RNA polymerase III transcription by the retinoblastoma protein.

Authors:  R J White; D Trouche; K Martin; S P Jackson; T Kouzarides
Journal:  Nature       Date:  1996-07-04       Impact factor: 49.962

Review 3.  Regulation of RNA polymerases I and III by the retinoblastoma protein: a mechanism for growth control?

Authors:  R J White
Journal:  Trends Biochem Sci       Date:  1997-03       Impact factor: 13.807

4.  Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database.

Authors:  S F Sener; A Fremgen; H R Menck; D P Winchester
Journal:  J Am Coll Surg       Date:  1999-07       Impact factor: 6.113

5.  Functional defects in the fanconi anemia pathway in pancreatic cancer cells.

Authors:  Michiel S van der Heijden; Jonathan R Brody; Eike Gallmeier; Steven C Cunningham; David A Dezentje; Dong Shen; Ralph H Hruban; Scott E Kern
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

6.  Molecular cloning and expression of a cDNA encoding a protein detected by the K1 antibody from an ovarian carcinoma (OVCAR-3) cell line.

Authors:  K Chang; I Pastan
Journal:  Int J Cancer       Date:  1994-04-01       Impact factor: 7.396

Review 7.  Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward?

Authors:  Shayna L Showalter; Timothy N Showalter; Agnes Witkiewicz; Robert Havens; Eugene P Kennedy; Tomas Hucl; Scott E Kern; Charles J Yeo; Jonathan R Brody
Journal:  Cancer Biol Ther       Date:  2008-04-21       Impact factor: 4.742

8.  Regulated expression of a diphtheria toxin A-chain gene transfected into human cells: possible strategy for inducing cancer cell suicide.

Authors:  I H Maxwell; F Maxwell; L M Glode
Journal:  Cancer Res       Date:  1986-09       Impact factor: 12.701

9.  Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Norihiro Sato; Noriyoshi Fukushima; Anirban Maitra; Christine A Iacobuzio-Donahue; N Tjarda van Heek; John L Cameron; Charles J Yeo; Ralph H Hruban; Michael Goggins
Journal:  Am J Pathol       Date:  2004-03       Impact factor: 4.307

10.  Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients.

Authors:  Amy Morck Thomas; Lynn M Santarsiero; Eric R Lutz; Todd D Armstrong; Yi-Cheng Chen; Lan-Qing Huang; Daniel A Laheru; Michael Goggins; Ralph H Hruban; Elizabeth M Jaffee
Journal:  J Exp Med       Date:  2004-08-02       Impact factor: 14.307

View more
  21 in total

1.  Rad51 promoter-targeted gene therapy is effective for in vivo visualization and treatment of cancer.

Authors:  Christopher M Hine; Andrei Seluanov; Vera Gorbunova
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

Review 2.  The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review.

Authors:  Federico Nichetti; Antonio Marra; Francesca Corti; Alessandro Guidi; Alessandra Raimondi; Natalie Prinzi; Filippo de Braud; Sara Pusceddu
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

Review 3.  New targeted therapies in pancreatic cancer.

Authors:  Andrada Seicean; Livia Petrusel; Radu Seicean
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

4.  Uptake and transfection with polymeric nanoparticles are dependent on polymer end-group structure, but largely independent of nanoparticle physical and chemical properties.

Authors:  Joel C Sunshine; Daniel Y Peng; Jordan J Green
Journal:  Mol Pharm       Date:  2012-09-27       Impact factor: 4.939

5.  Targeted therapies for pancreatic adenocarcinoma: Where do we stand, how far can we go?

Authors:  Dimitra Grapsa; Muhammad Wasif Saif; Konstantinos Syrigos
Journal:  World J Gastrointest Oncol       Date:  2015-10-15

6.  2011 Rita Schaffer lecture: nanoparticles for intracellular nucleic acid delivery.

Authors:  Jordan J Green
Journal:  Ann Biomed Eng       Date:  2012-03-27       Impact factor: 3.934

7.  The cytotoxic activity of the phage E protein suppress the growth of murine B16 melanomas in vitro and in vivo.

Authors:  Raúl Ortiz; Jose Prados; Consolacion Melguizo; Ana R Rama; Ana Segura; Fernando Rodríguez-Serrano; Houria Boulaiz; Fidel Hita; Antonio Martinez-Amat; Roberto Madeddu; Juan L Ramos; Antonia Aranega
Journal:  J Mol Med (Berl)       Date:  2009-07-05       Impact factor: 4.599

8.  Nanoparticle-delivered suicide gene therapy effectively reduces ovarian tumor burden in mice.

Authors:  Yu-Hung Huang; Gregory T Zugates; Weidan Peng; David Holtz; Charles Dunton; Jordan J Green; Naushad Hossain; Michael R Chernick; Robert F Padera; Robert Langer; Daniel G Anderson; Janet A Sawicki
Journal:  Cancer Res       Date:  2009-08-01       Impact factor: 12.701

9.  Small-Molecule End-Groups of Linear Polymer Determine Cell-type Gene-Delivery Efficacy.

Authors:  Joel Sunshine; Jordan J Green; Kerry P Mahon; Fan Yang; Ahmed A Eltoukhy; David N Nguyen; Robert Langer; Daniel G Anderson
Journal:  Adv Mater       Date:  2009-08-15       Impact factor: 30.849

10.  Poly(β-amino ester) nanoparticle delivery of TP53 has activity against small cell lung cancer in vitro and in vivo.

Authors:  Chandrashekhar D Kamat; Ron B Shmueli; Nick Connis; Charles M Rudin; Jordan J Green; Christine L Hann
Journal:  Mol Cancer Ther       Date:  2013-01-30       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.